An estimated 15%–20% of patients with breast carcinoma exhibit HER2 amplification, which predisposes them to higher rates of brain metastasis than those lacking HER2 overexpression, thereby creating a significant therapeutic challenge for this subgroup. This evidence concerns the gene ERBB2 and breast carcinoma.